Crescendo to Participate in Upcoming Investor Conferences

April 27, 2021 11:00 UTC

 

 
 

CAMBRIDGE, England--(BUSINESS WIRE)-- Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that senior members of the executive team will be participating at the following two investor conferences:

  • SVB Leerink Biopharma Private Company Connect Event, 6-7 May 2021
    Theodora Harold (CEO), Phil Bland-Ward (CDO) and Mike Booth (CFO) will be attending to meet investors to discuss the Company’s business strategy, technology, discovery and development programmes.
  • Bio€quity Europe 2021, 17-19 May
    Theodora Harold (CEO) and Mike Booth (CFO) will be attending, and Theodora will also be a panelist in the faculty session, BioCentury Scene Setter: Reading the Next Act, on Monday 17 May.

Both events will be virtual. If you are interested in meeting the team at these events, please contact the Company via email at investors@crescendobiologics.com.

Please refer to individual conference websites for further information and updated schedules.

-Ends-

About Crescendo Biologics

Crescendo Biologics is a clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody® for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anticancer effect whilst avoiding systemic toxicity.

The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit www.crescendobiologics.com and follow @HUMABODY.

Contacts

Crescendo Biologics
Theodora Harold, CEO
+ 44 (0)1223 497140
investors@crescendobiologics.com
media@crescendobiologics.com

Instinctif Partners
Melanie Toyne-Sewell, Siobhan Sanford, Nathan Billis
+ 44 (0)20 7457 2020
crescendo@instinctif.com

 
 

Source: Crescendo Biologics Ltd

Back to news